Skip to main content

Table 4 Patients and clinicopathological features between low and high mSAS

From: Predictive value of the surgical Apgar score on postoperative complications in advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by radical gastrectomy: a single-center retrospective study

Variables All patients N = 115 low mSAS < 8
83 (72.2%)
high mSAS ≥8
32 (27.8%)
p value
Age (yr) 63.3 (±10.8) 63.2 (±10.8) 63.8 (±10.9) 0.736
Gender     0.044
 Male 81 (70.4%) 63 (75.9%) 18 (56.3%)  
 Female 34 (29.6%) 20 (24.1%) 14 (43.8%)  
Body Mass Index (BMI) 22.3 (±3.3) 22.7 (±3.6) 21.1 (±2.8) 0.027
 BMI ≥ 22 60 (52.2%) 46 (55.4%) 14 (43.8%) 0.001
Diabetes Mellitus 9 (7.8%) 7 (8.4%) 2 (6.3%) 1
Smoking history 73 (63.5%) 58 (69.9%) 15 (46.9%) 0.030
American Society of Anesthesiologists Physical Status (ASA-PS)     0.703
 1 11 (9.6%) 7 (8.4%) 4 (12.5%)  
 2 94 (81.7%) 68 (81.9%) 26 (81.3%)  
 3 10 (8.7%) 8 (9.6) 2 (6.3%)  
Tumor locationa     0.097
 Upper 46 (40%) 38 (45.8%) 8 (25.0%)  
 Middle 39 (33.9%) 26 (31.3%) 13 (40.6%)  
 Lower 20 (17.4%) 11 (13.3%) 9 (28.1%)  
 Whole 10 (8.7%) 8 (9.6%) 2 (6.3%)  
ycStage     0.302
 I 3 (2.6%) 3 (3.6%) 0  
 II 47 (40.9%) 31 (37.3%) 16 (50.0%)  
 III 65 (56.5%) 49 (59.0%) 16 (50.0%)  
Neoadjuvant chemotherapy regimen     0.057
 S-1b and cisplatin 74 (64.3%) 51 (61.4%) 23 (71.9%)  
 S-1b and oxaliplatin 14 (12.2%) 8 (9.6%) 6 (18.8%)  
 S-1b, docetaxel and cisplatin 13 (11.3%) 10 (12.0%) 3 (9.4%)  
 Others 14 (12.2%) 14 (16.9%) 0  
Surgical Procedure     0.001
 Distal gastrectomy 29 (25.2%) 13 (15.7%) 16 (50.0%)  
 Total gastrectomy 83 (72.3%) 68 (81.9%) 15 (46.9%)  
Other 3 (2.6%) 2 (2.4%) 1 (3.1%)  
 Operation time (min) 337.1 (±111.1) 365.6 (±113.5) 263.4 (±59.8) <  0.001
Surgical Apgar score 6.25 (±1.1) 5.77 (±1.2) 7.50 (±0.67) <  0.001
modified Surgical Apgar Score 6.34 (±1.5) 5.65 (±1.2) 8.16 (±0.46) <  0.001
 Estimated blood loss (ml) 711.5 (±627.0) 898.1 (±644.3) 227.6 (±112.9) <  0.001
 Lowest mean arterial pressure 55.6 (±6.6) 54.8 (±6.5) 57.6 (±6.4) 0.034
 Lowest heart rate 58.7 (±8.4) 59.8 (±8.8) 56.0 (±6.7) 0.034
Extent of lymphadenectomy     0.023
 D2c 48 (41.7%) 31 (37.3%) 17 (53.1%)  
 D2 + d 40 (34.8%) 27 (32.5%) 13 (40.6%)  
 D3e 27 (23.5%) 25 (30.1%) 2 (6.3%)  
ypTa factor     0.346
 0 4 (3.5%) 3 (3.6%) 1 (3.1%)  
 T1a 1 (0.9%) 1 (1.2%) 0  
 T1b 13 (11.3%) 10 (12.0%) 3 (9.4%)  
 T2 17 (14.8%) 15 (18.1%) 10 (31.3%)  
 T3 51 (44.3%) 36 (43.4%) 15 (46.9%)  
 T4a 25 (21.7%) 15 (18.1%) 10 (31.3%)  
 T4b 4 (3.5%) 3 (3.6%) 1 (3.1%)  
ypNa factor     0.781
 0 39 (33.9%) 30 (36.1%) 9 (28.1%)  
 1 24 (20.9%) 18 (21.7%) 6 (18.8%)  
 2 26 (22.6%) 19 (22.9%) 7 (21.9%)  
 3 26 (22.6%) 16 (19.3%) 10 (31.3%)  
M factor     0.725
 0 104 (90.4%) 74 (89.2%) 30 (93.8%)  
 1 11 (9.6%) 9 (10.8%) 2 (6.3%)  
ypStagea     0.392
 0 3 (2.6%) 3 (3.6%) 0  
 I 19 (16.5%) 16 (19.3%) 3 (9.4%)  
 II 37 (32.3%) 25 (30.1%) 12 (37.5%)  
 III 45 (39.1%) 30 (36.1%) 15 (46.9%)  
 IV 11 (9.6%) 9 (10.8%) 2 (6.3%)  
postoperative complicationf ≥ IIIa 41 (35.7%) 35 (42.2%) 6 (18.8%) 0.029
Histological response of primary lesion     0.673
 0 2 (1.7%) 2 (2.4%) 0  
 1a 33 (28.7%) 24 (28.9%) 9 (28.1%)  
 1b 30 (26.1%) 22 (26.5%) 8 (25.0%)  
 2 47 (40.9%) 32 (38.6%) 15 (46.9%)  
 3 3 (2.6%) 3 (3.6%) 0  
  1. aAccording to the seventh edition of the International Union Against Cancer tumor, node, metastasis (TNM) classification system
  2. bTegafur/Gimeracil/Oteracil: Product name is TS-1
  3. cD2 lymphadenectomy: Dissection filed for distal gastrectomy: #1, #3a, #3b, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12aDissection filed for total gastrectomy: #1, #2, #3a, #3b, #4sa, #4sb, #4d, #5, #6, #7, #8a, #9, #10, #11p, #11d, #12a
  4. dD2+ lymphadenectomy: D2 plus either #16a2/#16b1
  5. eD3 lymphadenectomy: D2 plus both #16a2 and #16b1
  6. fAccording to Clavien-Dindo Classification